In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "Albany Molecular Research (AMRI) beat earnings and raised guidance then dropped up to 19% recently. What am I missing?"
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Ask a Fool: What's Behind Albany Molecular's Biggest Drop?
By Max Macaluso
–
May 30, 2013 at 7:48PM
NASDAQ: AMRI
Albany Molecular Research Inc.
Albany Molecular beat on earnings and raised guidance. So why did the market react so poorly?
Max Macaluso, Ph.D. and The Motley Fool have no position in any stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Albany Molecular Research Inc.
AMRI
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Biotech Stocks to Buy in March
The Cheapest Stocks in Biotech
3 Biotech Stocks the Market Hates May Rally
Today’s Top Biotech Stories: Albany Molecular Research, Rockwell Medical, and Celgene
Why Albany Molecular Research Inc. Shares Tumbled
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.